Navigation Links
Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium
Date:9/8/2011

s, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact    
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41-(0)21-321-01-11
Fax: +41-(0)21-321-01-69
mwagner@debiopharm.com

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44-(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Lena Evans
Account Executive
Tel:  +1-212-845-4262
Fax: +1-212-845-4260
lena.evans@russopartnersllc.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... of Outstanding Issues (LOI) from the European Medicines Agency,s ... the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained ... candidate being evaluated for weight loss. The ... were adequately addressed by the Company based in part ...
(Date:7/30/2014)... PARK, Md. , July 30, 2014 /PRNewswire-USNewswire/ ... biological components to interrogate biology, but such devices ... biology. As such, researchers have ... for in vitro metabolic engineering to ... on a chip. New devices are envisioned to ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... NCERC at Southern Illinois University Edwardsville ... on corn stover pretreatment methods at a U.S. ... D.C. , “Arun’s selection for presentation at ... to the success of our postdoctoral fellowship program,” ... foresight and vision of SIUE and the Illinois ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Calif., March 30 TorreyPines Therapeutics, Inc. (Nasdaq: ... District Court of the Southern District of New York ... of Axonyx Inc. ("Axonyx") against Axonyx and several of ... in 2006. The plaintiffs alleged that the defendants made ...
... March 30 BioMedical Enterprises, Inc. (BME), a rapidly ... of orthopaedic memory metal implants, announced today that it ... Sales and Marketing. BME specializes in nitinol implants ... ends together to promote bone union. The ...
... Stem Cell Trial to Show Dose-related Significant Improvement in ... Amorcyte, Inc. (Amorcyte) today announced data from its ... product for the treatment of damaged heart muscle following ... between cell dose and biologic effect. This is the ...
Cached Biology Technology:Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 3Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 4
(Date:7/30/2014)... A team of biologists, led by Clemson University associate ... marine pest that will pave the way for novel ... bio-adhesives for medical and industrial applications. , The team,s ... examined the last larval stage of barnacles that attaches ... natural, possibly polymeric material that acts as an underwater ...
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... and statistically significant improvements in clinical measures of ... the Etiology, Pathogenesis and Treatment of Parkinson's Disease ... positive interim results in patients with Parkinson's disease. ... statistically significant improvement in motor function on the ...
... discovered how a small molecule of RNA called microRNA ?a ... a key protein involved in the early development of heart ... the journal Nature, may aid scientists in their understanding of ... a heart cell, as well as offer researchers a way ...
... Paxinos and Dr Yuri Koutcherov of the Spinal Injuries ... Institute have been awarded ~$200,000 by the Christopher Reeve ... the rat spinal cord over the next two years. ... visit to Australia in 2003 and was impressed with ...
Cached Biology News:Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 2Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 3Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 4Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 5Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease 6MicroRNA tweaks protein that controls early heart development 2MicroRNA tweaks protein that controls early heart development 33D Atlas Will Help Navigate The Spinal Cord 2
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Full service including gene cloning, protien expression and purification of 1 liter culture....
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Protein 3D structure prediction, via threading. Easy to use....
Biology Products: